A handheld device that treats migraine attacks with puffs of air in a patient’s ears has been designated a breakthrough device by the FDA.
Tempe, Arizona-based Nocira said it is the first company to announce breakthrough device designation for treating migraine attacks in both chronic and non-chronic migraine patients ages 18 and up.
The device uses “gentle, controlled puffs of air in the ears” to subtly change pressure in the external ear canal, a drug-free technology that Nocira calls Automated Variable Pulse Insufflation (AVPI).